Terrone C, Cracco F, Porpiglia F et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006 Feb;49(2):324–31
Miles KA, London NJ, Lavelle JM et al. CT staging of renal carcinoma: a prospective comparison of
three dynamic computed tomography techniques. Eur J Radiol 1991;13(1):37–42
Krestin GP, Gross-Fengels W, Marincek B. The importance of magnetic resonance tomography in the diagnosis and staging of renal cell carcinoma.Radiology 1992;32(3):121–6
Remzi M, Marberger M. Renal tumor biopsies for evaluation of small renal tumors: why, in whom and how? Eur Urol 2009 Feb;55:359–67
Tsui KH, Shvarts O, Barbaric Z et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies.J Urol 2000;163(2):437–41.,
Blom JH, van Poppel H, Maréchal JM et al; EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881.Eur Urol 2009 Jan;55(1):28–34.
Cadeddu JA, Ono Y, Clayman RV et al. Laparoscopic nephrectomy for renal cell cancer: evaluation of efficacy and safety: a multicenter experience.Urology 1998 Nov;52(5):773–7.
van der Poel HG, Roukema JA, Horenblas S et al. Metastasectomy in renal cell carcinoma: A multicenter
retrospective analysis.Eur Urol 1999;35(3):197–203.
Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy.Scand J Urol Nephrol 2000 Aug;34(4):246–51.
Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial Lancet 2010 Feb 20;375(9715):641–8.
McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 2005 Jan;23(1):133–41.
Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 2003 Jul;349(5):427–34
Bellmunt J, Négrier S, Escudier B et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell
carcinoma.J Clin Oncol 2006 Jan;24(1):16–24.
Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 Jan;356(2):115–24
